Please ensure Javascript is enabled for purposes of website accessibility

Unity Biotech: Buy at the Low?

By Maxx Chatsko - Aug 22, 2019 at 10:09AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares have been mired in a nearly continuous slide for the last year. Is Wall Street's pessimism misplaced?

Unity Biotech (UBX 3.81%) is developing drug candidates to extend the number of years humans can live unburdened by disease, but investors might appreciate it if the small-cap pharma focused just a little bit more on extending the price of shares.

The stock is trading at all-time lows (though "all-time" is just since its IPO in mid-2018). The company's lead drug candidate delivered mixed results in a phase 1 clinical trial in June, although the company characterized the results as "promising" and is moving ahead with a phase 2 study.

Wall Street clearly isn't enamored, but Unity Biotech has a deep pipeline of preclinical assets and exited June with $128 million in cash. Besides, investors might be intrigued by a company attempting to enable healthy aging. Should investors consider the stock a buy at current lows?

Question marks drawn on brightly colored note cards.

Image source: Getty Images.

What does Unity Biotech do?

Unity Biotech wants to halt or reverse specific diseases driven by aging. The company's current focus is on developing drug candidates that eliminate senescent cells, or cells that are old and inefficient. The bodies of younger individuals tend to be more proficient at mopping up less productive cells and replacing them with new ones, but as we age, regenerative processes gradually break down. That plays a significant role in many diseases with an age component, such as vision loss, cardiovascular health, and most cancers.

In addition to eliminating senescent cells, Unity Biotech teases that it's conducting early-stage research into the biomolecular processes that contribute to mitochondrial dysfunction and the loss of youth-circulating factors. What does that mean?

Mitochondria produce chemical energy that can be readily used by cells; they play an essential role in health. While mitochondria live within most cells, they actually retain their own unique genomes different from your own. Certain mutations or errors in mitochondrial DNA have been linked to everything from autism to cancer to aging. It's inevitable that science will investigate ways to control, transplant, or genetically engineer mitochondria for therapeutic benefit, and Unity Biotech is keen to become a pioneer in that area.

Youth-circulating factors are exactly what they sound like: proteins ("factors") that circulate in the blood of younger organisms and drive regenerative processes. Studies have shown that exposing older mice to blood taken from younger mice can reduce and even reverse some of the effects of aging thanks to a cocktail of such proteins. It's not quite the fountain of youth, and isolating individual circulating factors that can deliver a therapeutic benefit in something as complex as the human body will prove difficult, but it's certainly worth investigating.

A doctor examining the knee of a patient.

Image source: Getty Images.

The state of the pipeline

For now, Unity Biotech is all-in on eliminating senescent cells. The lead drug candidate, UBX0101, is being developed as a potential treatment for osteoarthritis of the knee. Top-line results from a two-part, phase 1 clinical trial were announced in mid-June, although Wall Street sold on the news. 

In part A, researchers randomly assigned 48 patients to receive one of six doses of the drug candidate or a placebo. In part B, researchers assigned 30 patients to receive the highest dose of the drug candidate or a placebo. Patients in both parts of the study received a single administration of the drug candidate or a placebo, and were asked to measure pain and function on various point scales commonly used in the management of osteoarthritis, including the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). The observations were mixed at best.


Part A Results (One of Six Different Doses or Placebo)

Part B Results (Highest Dose or Placebo)

Pain, numerical rating scale

Dose-dependent and clinically meaningful reduction at 12 weeks



Dose-dependent and clinically meaningful reduction at 12 weeks

No difference at four weeks

Function, WOMAC

Dose-dependent and clinically meaningful reduction at 12 weeks


Stiffness, WOMAC

No changes

No changes

Data source: Press release.

It's important to note that "clinically meaningful" is not as high of a standard as "statistically significant." It's also important to note that based on the results published in the company's press release, there actually wasn't much of a dose-dependent response. In fact, the pain and function measurements using WOMAC consistently demonstrated that the placebo performed better than individuals taking any of the three lowest doses of UBX0101.

Unity Biotech moved beyond subjective measurements of pain and stiffness by also measuring inflammation from MRI exams (no difference was observed at any dose level) and various biomarkers related to senescent cells. In part A -- the part of the study with "clinically meaningful" pain reduction scores -- there were insufficient samples available to measure biomarkers. In part B -- the part of the study without any significant difference from the placebo -- half of the samples collected demonstrated that biomarkers were altered consistent with what might be expected if UBX0101 eliminated aging cells.

To be blunt, Unity Biotech got off to a messy start in the clinic. It needs to generate more data before investors start dreaming of halting age-related diseases. To be blunter, it appears UBX0101 probably won't deliver a therapeutic benefit to individuals with osteoarthritis of the knee. Even if researchers can measure that the drug candidate wipes out senescent cells, that doesn't matter much if it doesn't relieve symptoms. That would just mean the hypothesis -- eliminating aging cells can treat disease -- is incomplete or incorrect.

Nonetheless, the company said it plans to start a phase 2 trial before the end of 2019 and announce results in the second half of 2020.

Too few data, too risky of an investment

Investors will soon have more to look forward to than UBX0101. Unity Biotech expects to file an investigational new drug (IND) application for UBX1967 and UBX1325, which also take aim at senescent cells, in eye-diseases in early 2020. That could allow the company to begin phase 1 trials later next year. 

While it's good to see progress, investors cannot overlook the fact that there's simply not enough data to support the company's therapeutic approach. The business ended June with $128 million in cash, but it reported an operating loss of $44 million in the first half of 2019. Most of the operating expenses incurred are related to research and development, so Unity Biotech is furiously working to prove the validity of its approach -- but this biopharma stock remains much too risky at this time. Investors should wait for more data before considering owning this company.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Unity Biotechnology, Inc. Stock Quote
Unity Biotechnology, Inc.
$0.58 (3.81%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.